66 related articles for article (PubMed ID: 38559707)
1. Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.
Wellington K; Keam SJ
Drugs; 2006; 66(6):837-50. PubMed ID: 16706554
[TBL] [Abstract][Full Text] [Related]
2. Emerging impact of quercetin in the treatment of prostate cancer.
Ghafouri-Fard S; Shabestari FA; Vaezi S; Abak A; Shoorei H; Karimi A; Taheri M; Basiri A
Biomed Pharmacother; 2021 Jun; 138():111548. PubMed ID: 34311541
[TBL] [Abstract][Full Text] [Related]
3. In vitro combination effects of plant-derived quercetin with synthetic bicalutamide on prostate cancer and normal cell lines: in silico comparison.
Inala MSR; Pamidimukkala K
In Silico Pharmacol; 2024; 12(1):22. PubMed ID: 38559707
[TBL] [Abstract][Full Text] [Related]
4. Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer.
Li Y; Wang H; Pan Y; Wang S; Zhang Z; Zhou H; Xu M; Liu X
Front Endocrinol (Lausanne); 2023; 14():1125299. PubMed ID: 37143720
[TBL] [Abstract][Full Text] [Related]
5. Epigallocatechin-3-gallate and bicalutamide cause growth arrest and apoptosis in NRP-152 and NRP-154 prostate epithelial cells.
Morrissey C; Brown M; O'Sullivan J; Weathered N; Watson RW; Tenniswood M
Int J Urol; 2007 Jun; 14(6):545-51. PubMed ID: 17593102
[TBL] [Abstract][Full Text] [Related]
6. Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
Sekino Y; Oue N; Mukai S; Shigematsu Y; Goto K; Sakamoto N; Sentani K; Hayashi T; Teishima J; Matsubara A; Yasui W
Prostate; 2019 Feb; 79(2):234-242. PubMed ID: 30324761
[TBL] [Abstract][Full Text] [Related]
7. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
8. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
9. Identification of the hub genes associated with prostate cancer tumorigenesis.
Zhu H; Lin Q; Gao X; Huang X
Front Oncol; 2023; 13():1168772. PubMed ID: 37251946
[TBL] [Abstract][Full Text] [Related]
10. The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update.
Lotfi N; Yousefi Z; Golabi M; Khalilian P; Ghezelbash B; Montazeri M; Shams MH; Baghbadorani PZ; Eskandari N
Front Immunol; 2023; 14():1077531. PubMed ID: 36926328
[TBL] [Abstract][Full Text] [Related]
11. Combination Modality Using Quercetin to Enhance the Efficacy of Docetaxel in Prostate Cancer Cells.
Sharma S; Cwiklinski K; Mahajan SD; Schwartz SA; Aalinkeel R
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765857
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Protein-Protein Interactions for Intermolecular Bond Prediction.
Tam JZ; Palumbo T; Miwa JM; Chen BY
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234723
[TBL] [Abstract][Full Text] [Related]
13. The cell cycle gene centromere protein K (
Chen X; Shao Y; Li Y; Yang Z; Chen Y; Yu W; Shang Z; Wei W
Transl Cancer Res; 2022 May; 11(5):1099-1111. PubMed ID: 35706799
[TBL] [Abstract][Full Text] [Related]
14. CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting.
Liu Y; Yang X; Gan J; Chen S; Xiao ZX; Cao Y
Nucleic Acids Res; 2022 Jul; 50(W1):W159-W164. PubMed ID: 35609983
[TBL] [Abstract][Full Text] [Related]
15. The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor.
Copello VA; Burnstein KL
Oncogene; 2022 May; 41(20):2824-2832. PubMed ID: 35418689
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
